Loading patent…
AssigneesTechnion Research & Development Foundation Limited, Tel HaShomer Medical Research Infrastructure and Services Ltd.
InventorsKfir Oved, Eran Eden, Martin Akerman, Roy Noy, Michal Besser, Yoram Reiter
Estimating the term…
A method of determining responsiveness to cancer treatment is disclosed. The method comprises analyzing a frequency of tumor infiltrating lymphocytes (TILs) having a CD8+CD28−CD152− signature in a sample of the subject, wherein a frequency of TILs having the CD8+CD28−CD152− signature above a predetermined level is indicative of a positive responsiveness to cancer treatment. Other signatures reflecting responsiveness to cancer treatment are also disclosed. In addition, methods of treating cancer based on these signatures are also disclosed.
A method of predicting responsiveness to autologous adoptive cell transfer therapy in a subject having metastatic melanoma, the method comprising contacting tumor infiltrating lymphocytes (TILs) of a tumor sample isolated from the subject with an antibody which recognizes CD8, an antibody which recognizes CD28 and an antibody which recognizes CD152 so as to determine a frequency of TILs having a CD8+CD28−CD152− signature, wherein a frequency of TILs having said CD8+CD28-CD152− signature below 25% is predicative of a negative responsiveness to autologous adoptive cell transfer therapy.
Dependencies are inferred from the claim text.